Our Cigna Specialty Care Options^® (SCO) and Cigna Specialty Care Options Plus^® (SCO+) programs identify customers whose nononcology and oncology specialty medications are being administered in a higher-intensity setting (e.g., outpatient hospital) to determine whether a less-intensive site of care is clinically appropriate. These customers are identified at the time of prior authorization.

The SCO and SCO+ programs contain a medical necessity site-of-care review in accordance with our Medication Administration Site of Care coverage policy.

A complete list of the SCO and SCO+ drug list is available for provider’s reference.

When clinically appropriate, we redirect customers to a quality, less-intensive site of care, such as a contracted provider’s office, a customer’s home with infusion nurses, or a non-hospital-based ambulatory infusion center. In certain circumstances, procurement from a specialty pharmacy with which we have a reimbursement arrangement may be an option.

SCO and SCO+ drug list changes:

The drugs added in this expansion were already on the drug list but expanded to be included on both the SCO and SCO+ drug lists. The SCO and SCO+ drug list includes the following, effective September 1, 2026:

• Revtorpyk^TM (gedatolisib)
• Sarclissa Escena^TM (isatuximab-irfc)

Additionally, the following drugs will be added to both the drug lists effective January 1, 2027.

• Aranesp^® (Darbepoetin alfa, 1 microgram [non-ESRD use])
• Avtozma^® (tocilizumab-anoh)
• Libtayo^® (pegzilarginase-nbln)
• Nplate^® (romiplostim)
• Retacrit^® (epoetin alfa-epbx [for non-esrd use])
• Sarclissa Escena^TM (isatuximab-irfc)
• Tyenne IV^® (toclizumab-aazg)